Incyte (INCY) Projected to Post Quarterly Earnings on Thursday

Posted by Brenda Bartman on Oct 27th, 2026

Incyte (NASDAQ:INCY – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Incyte to announce earnings of ($3.64) per share and revenue of $1.47 billion for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the prior year, the company earned $1.57 earnings per share. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, analysts expect Incyte to post $1.97 EPS for the current fiscal year and $7.55 EPS for the next fiscal year.

Incyte Trading Down 2.1%

Shares of INCY stock opened at $113.31 on Tuesday. Incyte has a 12 month low of $84.02 and a 12 month high of $132.60. The stock has a market cap of $22.97 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 4.79 and a beta of 0.74. The company’s fifty day moving average price is $121.26 and its 200-day moving average price is $107.90.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

Positive Sentiment: Incyte presented new gastrointestinal cancer data at ESMO 2026, supporting the potential of its developing oncology portfolio and providing additional pipeline catalysts. Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Positive Sentiment: Incyte and Genmab agreed to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer. The partnership expands Incyte’s potential addressable market and strengthens its position in targeted gastrointestinal cancer therapy. Incyte and Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Positive Sentiment: H.C. Wainwright maintained its Buy rating, indicating continued confidence in Incyte’s prospects. H.C. Wainwright Sticks to Their Buy Rating for Incyte
Neutral Sentiment: Incyte said it views its KRAS G12D pancreatic cancer program as “neck and neck” with Revolution Medicines, highlighting meaningful competitive potential but also a closely contested development race. Incyte’s KRAS G12D Pancreatic Cancer Race
Negative Sentiment: Some sell-side brokerages continue to rate Incyte Hold, while valuation commentary questions whether the stock remains inexpensive after its strong multiyear advance. These views may be contributing to investor caution. Incyte Stock Rated Hold by Sell-Side Brokerages

Analyst Ratings Changes

INCY has been the topic of several research reports. Benchmark reissued a “buy” rating on shares of Incyte in a research note on Tuesday, October 13th. Royal Bank Of Canada raised their target price on shares of Incyte from $109.00 to $114.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Mizuho lifted their target price on shares of Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. TD Cowen lifted their target price on shares of Incyte from $138.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Finally, Oppenheimer reissued a “market perform” rating and issued a $120.00 price target on shares of Incyte in a research report on Tuesday, July 28th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $129.90.

Check Out Our Latest Research Report on INCY

Insider Buying and Selling at Incyte

In other news, insider Pablo Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the transaction, the insider directly owned 183,200 shares in the company, valued at $23,002,592. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick Mayes sold 41,899 shares of Incyte stock in a transaction on Friday, July 31st. The stock was sold at an average price of $119.46, for a total value of $5,005,254.54. Following the completion of the sale, the executive vice president directly owned 61,441 shares of the company’s stock, valued at $7,339,741.86. The trade was a 40.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 55,342 shares of company stock worth $6,659,208 over the last three months. Insiders own 16.20% of the company’s stock.

Incyte Company Profile

(Get Free Report)

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.